SUIC and VisionRenu Sign Strategic MOU to Accelerate AI Biotechnology and U.S. Capital Market Expansion

SUIC Worldwide Holdings Ltd. (OTC Markets: SUIC) and VisionRenu Biomedical Technology Co., Ltd. have announced the signing of a Strategic Memorandum of Understanding (MOU) to collaborate on AI-powered biotechnology, precision medicine, and international capital market initiatives. The agreement, disclosed in a press release, establishes a framework for combining SUIC's expertise in business acceleration and capital markets with VisionRenu's medical technology innovations in brain health and ophthalmic devices.

Under the MOU, the two companies will work together to accelerate VisionRenu's global commercialization and explore U.S. capital market opportunities. This includes strategic financing, business development, and potential listing on U.S. exchanges. Both companies view the agreement as the first step toward a long-term strategic partnership focused on innovation and sustainable growth.

The collaboration aligns with the rapid growth of AI in biotechnology, which is transforming fields such as gene editing, DNA synthesis, and precision medicine. AI enables faster discovery of disease-related genes, improves CRISPR precision, and shortens development cycles for therapeutics. Combined with automated DNA synthesis and robotic laboratories, AI is creating a new era of intelligent life science innovation through the Design-Build-Test-Learn (DBTL) platform.

Industry analysts expect AI-enabled biotechnology to become one of the world's largest innovation markets, creating multi-trillion-dollar opportunities across healthcare, drug discovery, synthetic biology, and advanced manufacturing. SUIC's strategic collaboration with VisionRenu, along with partnerships involving AI biotech startups supported by Taiwan's Ministry of Health and Welfare, positions the company to expand into this sector.

VisionRenu, headquartered in Taipei, Taiwan, specializes in medical devices for brain health and ophthalmic care. Its flagship product, the MagRenu® Transcranial Magnetic Stimulation (TMS) System, is approved by Taiwan's TFDA for treating depression. The company also develops proprietary ophthalmic laser technologies to address global demand for advanced vision care solutions. More information is available at https://www.vision-renu.com/.

SUIC Worldwide Holdings, based in New York, is a technology-enabled investment and business acceleration company focusing on acquiring and developing high-growth businesses. It supports portfolio companies through strategic investments, mergers, and access to international capital markets. Additional details can be found at https://sinounitedco.com/.

This press release contains forward-looking statements subject to risks and uncertainties. The MOU is non-binding, and there is no assurance that any definitive transaction will be completed. Readers are cautioned not to place undue reliance on these statements.